Randomized phase III study of S-1 plus oxaliplatin compared with S-1 plus cisplatin as first-line therapy for advanced or recurrent gastric cancer
Phase 3
- Conditions
- Advanced or recurrent gastric cancer
- Registration Number
- JPRN-jRCT2080220988
- Lead Sponsor
- Yakult Honsha Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Gastric cancer confirmed by histological diagnosis or cytologic diagnosis
-Advanced/Recurrent gastric cancer
-Not pretreated with chemotherapy drugs, immunotherapeutic drugs, or radiation therapy
-ECOG Performance Status 0 to 2
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method